Results
|
|
1.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(9):1579-86, 2016 Sep
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
|
|
|
2.
|
Safety of eptifibatide when added to bivalirudin during ST-segment elevation myocardial infarction. MedStar authors:
- Baker, Nevin C
- Escarcega, Ricardo O
- Lipinski, Michael J
- Magalhaes, Marco A
- Torguson, Rebecca
- Waksman, Ron
Year: 2014
Citation: - Cardiovascular Revascularization Medicine. 15(5):278-83, 2014 Jul-Aug.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Baker NC, Escarcega RO, Lipinski MJ, Magalhaes MA, Torguson R, Waksman R
|
|
|
3.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
